Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: Yahoo! Finance
lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. Given this risk, we thought we'd take a look at whether Artiva Biotherapeutics NASDAQ:ARTV ) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn. View our latest analysis for Artiva Biotherapeutics Does Artiva Biotherapeutics Have A Long Cash Runway? A company's cash runway is calculated by dividing its cash hoard by its cash burn. In March 2024, Artiva Biotherapeutics had US$62m in cash, and was debt-free. In the last year, its cash burn was US$50m. That means it had a cash runway of around 15 months as of March 2024. That's not too bad, but it's fair
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswire
- Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.MarketBeat
- Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.MarketBeat
- Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
ARTV
Sec Filings
- 9/13/24 - Form 4
- 9/13/24 - Form 4
- 9/13/24 - Form 4
- ARTV's page on the SEC website